He promoted PI-88 as a global cancer drug, and initiated the global ph3 trial, and to his credit, he obtained the funding for it.
It would appear that the Board have lost faith in this vision (probably due to low enrolment and the lack of a partner to step up) and have realised that PI-88 is a regional drug, and not worth the cost of a Global Ph3.
Therefore, its cap in hand to the regional player we go.
What is PI-88 worth?
I may be wrong (it appears that I have form on that count) but if I remember correctly it has cost PGL about 70m.
Anyway let’s see what happens. A particular trigger did not generate this ann. it was the Board decision. The prudent thing to do would be to have a regional partner in tow prior to the ann.
This Too Will Pass……….perhaps!!
PGL Price at posting:
0.0¢ Sentiment: None Disclosure: Held